AbbVie eyes Imbruvica expansion in CLL as Gazyva pairing hits its marks

AbbVie’s Imbruvica growth strategy in chronic lymphocytic leukemia centers on expanding use of the drug among previously untreated patients. And it now has some new data that should help it do that.